Additional file 3 of Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

Additional file 3: Table S1. Detailed information of the introduced immunotherapy cohorts. Table S2. Summary of clinical and tumor sample characteristics. Table S3. Summary of Next-Generation Sequencing Analyses. Table S4. Somatic Sequence Alterations. Table S5. Summary of intratumoral heterogeneity in patients and tumor regions. Table S6. Copy Number Alterations. Table S7. Summary of calculated intratumoral heterogeneity. Table S8. Neoantigen Predictions

附加文件3：表S1。 纳入免疫治疗队列的详细信息。表S2。 临床及肿瘤样本特征汇总。表S3。 下一代测序（Next-Generation Sequencing）分析汇总。表S4。 体细胞序列变异。表S5。 患者及肿瘤区域的肿瘤内异质性汇总。表S6。 拷贝数变异（Copy Number Alterations）。表S7。 计算所得肿瘤内异质性汇总。表S8。 新抗原预测